Compare ACAD & BXMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ACAD | BXMT |
|---|---|---|
| Founded | 1993 | 1966 |
| Country | US | US |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.9B | 3.3B |
| IPO Year | 2000 | 1998 |
| Metric | ACAD | BXMT |
|---|---|---|
| Price | $23.30 | $19.24 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 22 | 5 |
| Target Price | ★ $29.95 | $21.13 |
| AVG Volume (30 Days) | 1.2M | ★ 1.5M |
| Earning Date | 04-12-2026 | 05-14-2026 |
| Dividend Yield | N/A | ★ 9.64% |
| EPS Growth | ★ 467.57 | 154.70 |
| EPS | ★ 0.69 | 0.64 |
| Revenue | ★ $726,437,000.00 | N/A |
| Revenue This Year | $15.06 | $6.72 |
| Revenue Next Year | $11.34 | $2.58 |
| P/E Ratio | $33.59 | ★ $30.55 |
| Revenue Growth | ★ 40.45 | N/A |
| 52 Week Low | $14.08 | $16.51 |
| 52 Week High | $28.35 | $21.24 |
| Indicator | ACAD | BXMT |
|---|---|---|
| Relative Strength Index (RSI) | 42.40 | 45.55 |
| Support Level | $21.51 | $19.40 |
| Resistance Level | $26.23 | $19.83 |
| Average True Range (ATR) | 0.84 | 0.47 |
| MACD | -0.07 | -0.02 |
| Stochastic Oscillator | 40.04 | 34.14 |
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.
Blackstone Mortgage Trust Inc is a real estate finance company involved in the origination and purchase of senior loans collateralized by commercial properties in North America, Europe, and Australia. The vast majority of the company's asset portfolio is comprised of floating rate loans secured by priority mortgages. These mortgages are mainly derived from office, hotel, and manufactured housing properties. A percentage of the collateralized real estate properties are located in New York, California, and the United Kingdom. Blackstone Mortgage Trust is managed by a subsidiary of The Blackstone Group and benefits from the market data provided by its parent company. Nearly all of Blackstone Mortgage Trust's revenue is generated in the form of interest income.